SPARC.BO

Sun Pharma Advanced Research Company Limited (SPARC) is a biopharmaceutical firm dedicated to the research and development of innovative pharmaceutical solutions, operating both within India and globally. Its therapeutic focus encompasses a range of critical health conditions, including oncology, neurodegenerative disorders, eye diseases (ophthalmology), skin conditions (dermatology), and immunological ailments. The company currently markets several key products: Elepsia XR, an extended-release formulation of levetiracetam used as an anti-epileptic drug for treating epilepsy; Xelpros, a latanoprost ophthalmic emulsion prescribed for open-angle glaucoma or ocular hypertension; and Phenobarbital injection, utilized for the management of neonatal seizures. SPARC's pipeline also features several promising drug candidates undergoing clinical trials. In Phase 3 trials, it is advancing SDN-037, a difluprednate formulation designed to address inflammation and pain following ocular surgery, alongside PDP-716, aimed at treating glaucoma. Furthermore, Vodobatinib (SCO-088) has completed Part A of its Phase 1 study for resistant chronic myelogenous leukemia, while another Vodobatinib variant (SCC-138) is in Phase 2 for Parkinson's disease. Other developments include SCD-044, in Phase 2 for psoriasis and atopic dermatitis, and SCO-120, which is in Phase 1 for metastatic breast cancer that is hormone receptor-positive and human epidermal receptor 2 negative. Established in 2006, the company's headquarters are located in Mumbai, India.